Read + Share
Xiong S, Liu F, Sun J, Gao S, et al. Abrogation of USP9X is a potential strategy to decrease PEG10 levels and impede
tumor progression in cutaneous T-cell lymphoma. J Invest Dermatol 2024 Apr 25:S0022-202X(24)00307.
PMID: 38677662
|
 |
|
Xiong S, Liu F, Sun J, Gao S, et al. Abrogation of USP9X is a potential strategy to decrease PEG10 levels and impede
tumor progression in cutaneous T-cell lymphoma. J Invest Dermatol 2024 Apr 25:S0022-202X(24)00307.
PMID: 38677662
|
|
|
|